Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The present invention relates t o BMPs (bone morphogenetic proteins) which regulate metabolic homeostasis of iron, fats and carbohydrates. In particular, the present invention relates t o methods for treating a disease of iron metabolism or a disease comprising abnormally high or low hepcidin levels or abnormally high or abnormally low iron levels using a BMP agonist or antagonist. The present invention further relates t o methods for treating a disease of fat or carbohydrate metabolism using a BM Pagonist or antagonist. The present invention further relates t o methods for treating a disease of iron metabolism or treating a disease of fat or carbohydrate metabolism by inhibition of the interaction between BMPs and erythroferrone (ERFE) / FAM 132b.

Type

Patent

Publication Date

12/12/2019

Addresses

Kirsty McHugh, University of Oxford, Jenner Institute, ORCB Old Road, Oxford, NA, OX37DQ, United Kingdom

Keywords

BMP, erythroferrone, iron, thalassemia, treatment, antibody